Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Beckman Coulter announced its commitment to support the U.S. government's plan to invest over $12 billion in COVID-19 testing by providing a high-throughput, $4 antigen test, Access SARS-CoV-2 Ag, aimed at mass screening. This test boasts a 93% positive predictive agreement and a 100% negative predictive agreement, with results available in 30 minutes. Targeted for high-risk settings, the test promotes equity in COVID-19 testing and aids in reopening schools and businesses safely.
Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will present at the Barclays Global Healthcare Conference on March 11, 2021, at 11:30 a.m. ET. The presentation will be available via a simultaneous webcast on Danaher's official website.
Danaher is a leading global innovator in science and technology, focusing on complex challenges in healthcare, environmental, and applied markets. The company employs around 69,000 associates and operates more than 20 companies under the Danaher Business System.
On February 23, 2021, Danaher Corporation (NYSE: DHR) announced the approval of a quarterly cash dividend of $0.21 per share for common stock, payable on April 30, 2021, to shareholders of record by March 26, 2021. Additionally, the company approved dividends for its preferred stock, including $11.875 per share for 4.75% Series A and $12.50 per share for 5.00% Series B, both payable on April 15, 2021, to holders of record by March 31, 2021.
Danaher Corporation (NYSE: DHR) announced that its President and CEO, Rainer M. Blair, will speak at the Cowen Healthcare Conference on March 1, 2021, at 11:40 a.m. ET. The presentation will be accessible via a live webcast on www.danaher.com. Danaher is a prominent global innovator in science and technology, focusing on solving complex challenges in healthcare and other sectors, supported by its diverse workforce of about 69,000 associates.
Cytiva has acquired Vanrx Pharmasystems, a Canadian firm specializing in robotic aseptic filling machines, marking its first acquisition since becoming an operating company of Danaher in April 2020. This acquisition aligns with global trends towards smaller batch manufacturing and personalized therapies in the growing USD 300 billion biologics market. The addition enhances Cytiva's solutions from drug development to drug product, facilitating faster delivery of therapies to patients. Vanrx's expertise in aseptic filling complements Cytiva's existing manufacturing capabilities.
Danaher Corporation (NYSE: DHR) reported strong financial results for Q4 and full year 2020. Q4 net earnings reached $1.2 billion ($1.66 per share), up 55% year-over-year, while revenues climbed 39% to $6.8 billion. Full year net earnings totaled $3.6 billion ($4.89 per share), reflecting a 50% increase, with total revenues at $22.3 billion, a 24.5% rise. The company anticipates mid to high-teens non-GAAP core revenue growth for Q1 2021 and low-double digits for the full year. The acquisition of Cytiva significantly bolstered Danaher's market position and long-term value.
Beckman Coulter announced the launch of the DxH 560 AL, a compact tabletop analyzer designed for small to mid-sized laboratories. This innovative device features Auto-Loading functionality, allowing for continuous sample addition of up to 50, while minimizing manual tasks and resource usage. It requires only 17 μL of blood, making it ideal for difficult-to-draw patients, and delivers results in under 60 seconds. The DxH 560 AL aims to provide large laboratory efficiency at a lower cost, enhancing productivity without exceeding budgetary constraints.
Beckman Coulter announced the launch of the DxH 560 AL, a tabletop analyzer designed for small to mid-sized laboratories. This innovative device features auto-loading functionality, accommodating up to 50 samples and requiring only a 17 μL sample volume, among the lowest in the market. The DxH 560 AL provides results in under 60 seconds, enhancing efficiency. It also includes advanced security features for patient data protection. The analyzer is part of the DxH 500 series, offering high-throughput capabilities while remaining budget-friendly.
On January 13, 2021, Danaher Corporation (NYSE: DHR) announced strong financial performance for Q4 2020 during the J.P. Morgan Healthcare Conference. The company expects core revenue growth, including Cytiva, to exceed previous guidance, driven by robust results in Life Sciences and Diagnostics segments. Estimated revenues rose approximately 38.5% year-over-year, with non-GAAP core revenue growth estimated at 15%. Danaher will report full earnings on January 28, 2021.
Danaher Corporation (NYSE: DHR) will have its President and CEO, Rainer M. Blair, present at the J.P. Morgan Healthcare Conference on January 13, 2021, at 10:50 a.m. ET. This presentation will be available via a live audio webcast and will be archived for later access on Danaher’s website.
As a leader in science and technology, Danaher focuses on solving complex challenges across healthcare and environmental markets, employing over 67,000 associates committed to improving quality of life globally.